Optina Diagnostics

📍 Montréal, Canada🗓 Founded 2011👥 43 employees💰 Last funded Jul 2018
Medical Device🌐 optinadx.com
Website LinkedIn
Optina’s Retinal Deep Phenotyping platform addresses the major challenges faced by the healthcare system related to an aging population.   Recently, Optina was granted breakthrough device designation by the FDA for our first indication in Alzheimer’s Disease detection which enables a dramatic improvement in the diagnostic accuracy of dementia.   Our ecosystem comprised of a proprietary platform and a network of eye clinics creates a new and efficient means for simple patient stratification. The ecosystem allows for the collection of data rich retinal images with 30X more information than current retinal imaging platforms.   Algorithm development utilizes a ground truth that is based on specifically characterized patients from leading institutions around the world.   With our developing product pipeline, Optina continues to bring clarity and accessibility to early stage diagnosis, improving the life of millions.
3
Total investors
1
Early stage
0
Mid stage
2
Late stage
2011
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Investor activity2012–2018 · investors recorded per year
2012120182
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Optina Diagnostics?
Optina Diagnostics has 3 investors on record on gritt.io, including 1 early-stage backers and 2 late-stage investors.
When did Optina Diagnostics last raise funding?
The most recent investment in Optina Diagnostics recorded on gritt.io was in July 2018.
When was Optina Diagnostics founded?
Optina Diagnostics was founded in 2011.
What industry is Optina Diagnostics in?
Optina Diagnostics operates in Medical Device. Find similar Medical Device investors on gritt.io.
Where is Optina Diagnostics based?
Optina Diagnostics is headquartered in Montréal, Canada.